Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

Video content above is prompted by the following:

• What are the available first- or second-line treatment options for HR+ advanced/metastatic breast cancer? (CDK4/6i +/- ET, etc.)
• What is the rationale for using CDK4/6i and ET in the front line?
• What are the main considerations when selecting frontline therapy? (bone metastases, visceral crisis, menopause status, recurrence score, nodal status, molecular phenotype, etc)
• Primary results from the Phase II RIGHT Choice trial
• SABCS PS2-06: Lu et al., RIGHT Choice trial subanalysis by intrinsic subtype & gene & signature expression.
• Real-world treatment outcomes (CDK4/6 inhibitors + endocrine therapy)
• OS analysis of first-line CDK4/6 inhibitors in real-world cohort
• What are the CDK4/6i options? Please briefly mention the main clinical trials and recent data:

1. Ribociclib - MONALEESA-2, MONALEESA-7, MONALEESA-3
2. ctDNA associated with PFS and OS in MONALEESA-3 (ML-3). 
3. Abemaciclib - MONARCH-3
4. Final OS Analysis of Monarch 2
5. Palbociclib - PALOMA-2, PARSIFAL
6. Nationwide real-world practice pattern and clinical data of palbociclib
7. SABCS 2024 LB1-03: Loibl et al, Primary results of the randomised phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy - PADMA study.
8. Lerociclib: LEONARDA-1
9. LEONARDA-2: Lerociclib plus letrozole
10. How do the data for the 3 CDK4/6i compare?